NO20052216L - Smertestillende midler - Google Patents

Smertestillende midler

Info

Publication number
NO20052216L
NO20052216L NO20052216A NO20052216A NO20052216L NO 20052216 L NO20052216 L NO 20052216L NO 20052216 A NO20052216 A NO 20052216A NO 20052216 A NO20052216 A NO 20052216A NO 20052216 L NO20052216 L NO 20052216L
Authority
NO
Norway
Prior art keywords
heat shock
relates
pain relief
painkillers
polypepids
Prior art date
Application number
NO20052216A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052216D0 (no
Inventor
Anthony Robert Milnes Coates
Original Assignee
Helperby Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helperby Therapeutics Ltd filed Critical Helperby Therapeutics Ltd
Publication of NO20052216D0 publication Critical patent/NO20052216D0/no
Publication of NO20052216L publication Critical patent/NO20052216L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20052216A 2002-11-08 2005-05-09 Smertestillende midler NO20052216L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0226105.5A GB0226105D0 (en) 2002-11-08 2002-11-08 Pain relief agents
PCT/GB2003/004774 WO2004041304A2 (en) 2002-11-08 2003-11-05 Pain relief agents

Publications (2)

Publication Number Publication Date
NO20052216D0 NO20052216D0 (no) 2005-05-09
NO20052216L true NO20052216L (no) 2005-08-05

Family

ID=9947469

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052216A NO20052216L (no) 2002-11-08 2005-05-09 Smertestillende midler

Country Status (17)

Country Link
US (1) US7744906B2 (is)
EP (1) EP1562625A2 (is)
JP (1) JP4607593B2 (is)
KR (1) KR20050086465A (is)
CN (1) CN1735427A (is)
AU (1) AU2003279454B2 (is)
BR (1) BR0316053A (is)
CA (1) CA2503964A1 (is)
CO (1) CO5640148A2 (is)
GB (2) GB0226105D0 (is)
IS (1) IS7862A (is)
MX (1) MXPA05004973A (is)
NO (1) NO20052216L (is)
NZ (1) NZ539867A (is)
RU (1) RU2005117635A (is)
WO (1) WO2004041304A2 (is)
ZA (1) ZA200503615B (is)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005204979B2 (en) * 2004-01-16 2010-10-21 Cbio Limited Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion
JP2007517808A (ja) * 2004-01-16 2007-07-05 キュビオ リミテッド Ｔｏｌｌ様受容体誘導性のサイトカインおよびケモカイン分泌のシャペロニン１０調節
GB0803369D0 (en) 2008-02-25 2008-04-02 Helperby Therapeutics Ltd Biological materials and uses thereof
GB201118201D0 (en) * 2011-10-21 2011-12-07 Helperby Therapeutics Ltd Novel peptides
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
CN105473133A (zh) 2013-04-30 2016-04-06 欧缇托匹克公司 干粉制剂及使用方法
GB201700557D0 (en) * 2017-01-12 2017-03-01 Peptinnovate Ltd Novel peptides
US12358957B2 (en) 2017-01-12 2025-07-15 Revolo Biotherapeutics Limited Method for the acute treatment of atopic dermatitis and allergic skin hypersensitivity
GB201700555D0 (en) 2017-01-12 2017-03-01 Peptinnovate Ltd Method for the treatment of a relapsing-remitting condition
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
EP3684338A4 (en) 2017-09-22 2021-06-23 Otitopic Inc. DRY POWDER COMPOSITIONS WITH MAGNESIUM STEARATE

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
DK171727B1 (da) 1978-12-22 1997-04-14 Biogen Inc Rekombinante hepatitis B virus DNA-molekyler, værtsorganismer transformeret hermed, HBV-antigenspecifikke polypeptider, DNA-sekvenser kodende for HBV-antigenspecifikke polypeptider, metoder til påvisning af hepatitis B virus-antistoffer, metoder til fremstilling af nævnte DNA-molekyler, fremgangsmåder til fremstilling af nævnte polypeptider og midler til påvisning af HBV-infektion
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
ES2233938T3 (es) * 1993-11-30 2005-06-16 The University Of Queensland Chaperonina 10.
CA2176948C (en) 1993-11-30 2007-05-15 Halle Morton Chaperonin 10
IT1271074B (it) 1994-11-21 1997-05-26 Italfarmaco Spa Peptidi ad attivita' antiinfiammatoria
JP4484969B2 (ja) * 1996-11-26 2010-06-16 ヌベンタ バイオファーマスティカル コーポレイション ストレスタンパク質を含む組成物を使用する免疫応答
JP2002508156A (ja) 1997-12-31 2002-03-19 ストレスジェン バイオテクノロジーズ コーポレイション Ｈｓｐ６０ファミリーのＳｔｒｅｐｔｏｃｏｃｃｕｓ熱ショックタンパク質
BR9907228A (pt) * 1998-01-23 2000-10-24 Nat Jewish Med & Res Center Uso de uma proteìna de choque térmico, processo para proteger um mamìfero de uma doença, formulação para proteger um mamìfero de desenvolver uma doença, uso de uma molécula de ácido nucleico, e processo para prescrever um tratamento para hiper-sensibilidade das vias aéreas ou limitação do fluxo de ar associado com uma doença envolvendo resposta inflamatória
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
EP1196772A2 (en) * 1999-07-08 2002-04-17 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
GB0028122D0 (en) 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
GB0803369D0 (en) 2008-02-25 2008-04-02 Helperby Therapeutics Ltd Biological materials and uses thereof

Also Published As

Publication number Publication date
GB2391477B (en) 2004-12-22
AU2003279454B2 (en) 2008-06-19
GB0226105D0 (en) 2002-12-18
JP2006514001A (ja) 2006-04-27
ZA200503615B (en) 2007-02-28
CO5640148A2 (es) 2006-05-31
NZ539867A (en) 2008-06-30
US7744906B2 (en) 2010-06-29
GB2391477A (en) 2004-02-11
WO2004041304A3 (en) 2004-07-29
US20060252681A1 (en) 2006-11-09
AU2003279454A1 (en) 2004-06-07
KR20050086465A (ko) 2005-08-30
JP4607593B2 (ja) 2011-01-05
IS7862A (is) 2005-05-24
MXPA05004973A (es) 2005-11-23
CA2503964A1 (en) 2004-05-21
GB0325782D0 (en) 2003-12-10
BR0316053A (pt) 2005-09-20
WO2004041304A2 (en) 2004-05-21
EP1562625A2 (en) 2005-08-17
CN1735427A (zh) 2006-02-15
NO20052216D0 (no) 2005-05-09
RU2005117635A (ru) 2006-01-20

Similar Documents

Publication Publication Date Title
BR0313555A (pt) Aplicação de inibidores de ikb-cinase na terapia da dor
BR0309544A (pt) Preparação farmacêutica contendo oxicodona e naloxona
HUP0401534A2 (hu) Módosított humán IX. faktor
ATE446313T1 (de) Muteine von tränen-lipocalin
NO995002L (no) Modifiserte TNF-<alfa>-molekyler, DNA som koder for slike modifiserte TNF-<alfa>-molekyler og vaksiner omfattende slike TNF- <alfa>-molekyler og DNA
NO992102D0 (no) Peptidblanding, samt farmasøytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
WO2003062273A3 (en) Modulator of the notch signalling pathway and use thereof in medical treatment
ATE189961T1 (de) Impfstoff gegen mycobakterielle infektionen
BR0316053A (pt) Uso de um polipeptìdeo de choque térmico e/ou uma sequência de ácido nucléico codificadora, e, método de aliviar a dor
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
HUP0302481A2 (hu) Virulencia gének, fehérjék és alkalmazásuk
NO20051983D0 (no) 3-fenyl-substituert pyridoindolon, fremstilling derav og terapeutisk anvendelse derav.
EP1663201A4 (en) USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
PT1290160E (pt) Polipeptideos pellino humanos
DK1520587T3 (da) Allergivaccinesammensætning, fremgangsmåde til fremstilling deraf og anvendelse deraf til allergibehandling
NO331083B1 (no) Anvendelse av en inhibitor av IL-18, en ekspresjonsvektor som omfatter den kodende sekvensen til en inhibitor av IL-18 og en ekspresjonsvektor for a indusere og/eller forsterke den endogene produksjonen av en inhibitor av IL-18 i en celle, til fremstillingen av et legemiddel for behandling og/eller forhindring av kardiomyopati
IS7798A (is) Efnasambönd, lyfjablöndur og aðferðir
ATE434435T1 (de) Pharmazeutische zubereitungen enthaltend modafinil
WO2001043693A3 (en) Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
ITVR20020123A1 (it) Apparecchiatura per il controllo della quantita` di materiale chirurgico utilizzato in sala operatoria.
BRPI0411168A (pt) composição para o tratamento dos cabelos, usos de uma composição e método de tratamento dos cabelos
ATE270551T1 (de) Kombinationspräparat aus 2-methylthiazolidin-2,4- dicarbonsäure und paracetamol
NO20060637L (no) Autologe selv-toleranse induserende celler av monocytisk opprinnelse og deres anvendelse i farmasoytiske preparater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application